<DOC>
	<DOCNO>NCT00310531</DOCNO>
	<brief_summary>The aim trial investigate whether Menostar patch safe effective prevention bone loss postmenopausal woman raloxifen , drug already registered prevention treatment osteoporosis .</brief_summary>
	<brief_title>3-year Study Menostar Versus Evista Prevent Osteoporosis Post-menopausal Women</brief_title>
	<detailed_description>The study previously post Schering AG , Germany . Schering AG , Germany rename Bayer Schering Pharma AG , Germany.Bayer Schering Pharma AG , Germany sponsor trial .</detailed_description>
	<mesh_term>Osteoporosis</mesh_term>
	<mesh_term>Bone Diseases , Metabolic</mesh_term>
	<mesh_term>Raloxifene Hydrochloride</mesh_term>
	<mesh_term>Estradiol</mesh_term>
	<mesh_term>Polyestradiol phosphate</mesh_term>
	<mesh_term>Estradiol 3-benzoate</mesh_term>
	<mesh_term>Estradiol 17 beta-cypionate</mesh_term>
	<mesh_term>Estradiol valerate</mesh_term>
	<criteria>Last ( regular ) menstrual period 5 year ago Relative good state health Intact , normal uterus Bone musculoskeletal disease Clinically significant vertebral fracture within last 12 month Preexisting cardiovascular disease ( e.g . uncontrolled high/low blood pressure , stroke , thromboembolic event etc ) Uncontrolled diabetes mellitus ( treated insulin ) Uncontrolled thyroid disorder Relevant renal disorder significant liver dysfunction ( include cholestasis ) History alcohol drug abuse History immobilization 2 month last 6 month Smoking 10 cigarette per day Unexplained uterine bleed Known suspect malignant premalignant disease ( e.g . cancer breast uterus , melanoma )</criteria>
	<gender>Female</gender>
	<minimum_age>55 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>December 2014</verification_date>
</DOC>